APO RESEARCH · REPORT
Olanzapine
Olanzapine is an atypical antipsychotic drugs, it is suitable for schizophrenia and other severe positive symptoms (for example: delusions, hallucinations, thought disorder, hostility and suspicion) and / or negative symptoms (such as: apathy acute and maintenance treatment, emotional and social withdrawal, poverty of speech) psychosis. In this report, we research and analyze the olanzapine, which used for manufacturing the olanzapine tablets.
Product & engineering
Understand the product.
Olanzapine is an atypical antipsychotic drugs, it is suitable for schizophrenia and other severe positive symptoms (for example: delusions, hallucinations, thought disorder, hostility and suspicion) and / or negative symptoms (such as: apathy acute and maintenance treatment, emotional and social withdrawal, poverty of speech) psychosis. In this report, we research and analyze the olanzapine, which used for manufacturing the olanzapine tablets.
Selected research
Industry Research
Olanzapine Industry Research Report 2026
Market perspective
Olanzapine is an atypical antipsychotic drugs, it is suitable for schizophrenia and other severe positive symptoms (for example: delusions, hallucinations, thought disorder, hostility and suspicion) and / or negative symptoms (such as: apathy acute and maintenance treatment, emotional and social withdrawal, poverty of speech) psychosis. In this report, we research and analyze the olanzapine, which used for manufacturing the olanzapine tablets.
Global Olanzapine key players include Lilly, Teva Pharmaceutical, Dr. Reddy's Laboratories, Apotex Inc, Hansoh Pharmaceutical, etc. Global top five manufacturers hold a share over 85%.
North America is the largest market, with a share over 70%, followed by Asia, which has a share over 25%.
Read the full market overview
In terms of product, Patent is the largest segment, with a share about 55%. And in terms of application, the largest application is Olanzapine Tablets, followed by Daily Commodities, etc.
Report Scope
This report quantifies the global Olanzapine market in terms of revenue (US$ million) and, where applicable, sales volume (Kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Olanzapine Market by Company
Lilly
Teva Pharmaceutical
Dr. Reddy's Laboratories
Apotex Inc.
Mylan Pharmaceuticals
Par Pharmaceutical
Aurobindo Pharma
Torrent Pharmaceuticals
Jubilant Lifesciences
Sun Pharmaceutical
Sandoz
Hansoh Pharmaceutical
WATSON Pharmaceuticals(Changzhou)
Zhejiang Langhua Pharmaceuticals
Olanzapine Segment by Type
Patent
Generics
Olanzapine Segment by Application
Olanzapine Tablets
Others
Olanzapine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Olanzapine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Olanzapine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Olanzapine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Olanzapine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Olanzapine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Olanzapine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Patent
- Generics
Applications
- Olanzapine Tablets
- Others
Companies covered
- Lilly
- Teva Pharmaceutical
- Dr. Reddy's Laboratories
- Apotex Inc.
- Mylan Pharmaceuticals
- Par Pharmaceutical
- Aurobindo Pharma
- Torrent Pharmaceuticals
- Jubilant Lifesciences
- Sun Pharmaceutical
- Sandoz
- Hansoh Pharmaceutical
- WATSON Pharmaceuticals(Changzhou)
- Zhejiang Langhua Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Olanzapine Market Size (2021-2032)
- 2.2.2 Global Olanzapine Sales (2021-2032)
- 2.2.3 Global Olanzapine Market Average Price (2021-2032)
- 2.3 Olanzapine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Patent
- 2.3.3 Generics
- 2.4 Olanzapine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Olanzapine Tablets
- 2.4.3 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Olanzapine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Olanzapine Sales (Kg) of Manufacturers (2021-2026)
- 3.3 Global Olanzapine Revenue of Manufacturers (2021-2026)
- 3.4 Global Olanzapine Average Price by Manufacturers (2021-2026)
- 3.5 Global Olanzapine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Olanzapine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Olanzapine, Product Type & Application
- 3.8 Global Manufacturers of Olanzapine, Established Date
- 3.9 Global Olanzapine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Lilly
- 4.1.1 Lilly Company Information
- 4.1.2 Lilly Business Overview
- 4.1.3 Lilly Olanzapine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Lilly Olanzapine Product Portfolio
- 4.1.5 Lilly Recent Developments
- 4.2 Teva Pharmaceutical
- 4.2.1 Teva Pharmaceutical Company Information
- 4.2.2 Teva Pharmaceutical Business Overview
- 4.2.3 Teva Pharmaceutical Olanzapine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Teva Pharmaceutical Olanzapine Product Portfolio
- 4.2.5 Teva Pharmaceutical Recent Developments
- 4.3 Dr. Reddy's Laboratories
- 4.3.1 Dr. Reddy's Laboratories Company Information
- 4.3.2 Dr. Reddy's Laboratories Business Overview
- 4.3.3 Dr. Reddy's Laboratories Olanzapine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Dr. Reddy's Laboratories Olanzapine Product Portfolio
- 4.3.5 Dr. Reddy's Laboratories Recent Developments
- 4.4 Apotex Inc.
- 4.4.1 Apotex Inc. Company Information
- 4.4.2 Apotex Inc. Business Overview
- 4.4.3 Apotex Inc. Olanzapine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Apotex Inc. Olanzapine Product Portfolio
- 4.4.5 Apotex Inc. Recent Developments
- 4.5 Mylan Pharmaceuticals
- 4.5.1 Mylan Pharmaceuticals Company Information
- 4.5.2 Mylan Pharmaceuticals Business Overview
- 4.5.3 Mylan Pharmaceuticals Olanzapine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Mylan Pharmaceuticals Olanzapine Product Portfolio
- 4.5.5 Mylan Pharmaceuticals Recent Developments
- 4.6 Par Pharmaceutical
- 4.6.1 Par Pharmaceutical Company Information
- 4.6.2 Par Pharmaceutical Business Overview
- 4.6.3 Par Pharmaceutical Olanzapine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Par Pharmaceutical Olanzapine Product Portfolio
- 4.6.5 Par Pharmaceutical Recent Developments
- 4.7 Aurobindo Pharma
- 4.7.1 Aurobindo Pharma Company Information
- 4.7.2 Aurobindo Pharma Business Overview
- 4.7.3 Aurobindo Pharma Olanzapine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Aurobindo Pharma Olanzapine Product Portfolio
- 4.7.5 Aurobindo Pharma Recent Developments
- 4.8 Torrent Pharmaceuticals
- 4.8.1 Torrent Pharmaceuticals Company Information
- 4.8.2 Torrent Pharmaceuticals Business Overview
- 4.8.3 Torrent Pharmaceuticals Olanzapine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Torrent Pharmaceuticals Olanzapine Product Portfolio
- 4.8.5 Torrent Pharmaceuticals Recent Developments
- 4.9 Jubilant Lifesciences
- 4.9.1 Jubilant Lifesciences Company Information
- 4.9.2 Jubilant Lifesciences Business Overview
- 4.9.3 Jubilant Lifesciences Olanzapine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Jubilant Lifesciences Olanzapine Product Portfolio
- 4.9.5 Jubilant Lifesciences Recent Developments
- 4.10 Sun Pharmaceutical
- 4.10.1 Sun Pharmaceutical Company Information
- 4.10.2 Sun Pharmaceutical Business Overview
- 4.10.3 Sun Pharmaceutical Olanzapine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Sun Pharmaceutical Olanzapine Product Portfolio
- 4.10.5 Sun Pharmaceutical Recent Developments
- 4.11 Sandoz
- 4.11.1 Sandoz Company Information
- 4.11.2 Sandoz Business Overview
- 4.11.3 Sandoz Olanzapine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Sandoz Olanzapine Product Portfolio
- 4.11.5 Sandoz Recent Developments
- 4.12 Hansoh Pharmaceutical
- 4.12.1 Hansoh Pharmaceutical Company Information
- 4.12.2 Hansoh Pharmaceutical Business Overview
- 4.12.3 Hansoh Pharmaceutical Olanzapine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Hansoh Pharmaceutical Olanzapine Product Portfolio
- 4.12.5 Hansoh Pharmaceutical Recent Developments
- 4.13 WATSON Pharmaceuticals(Changzhou)
- 4.13.1 WATSON Pharmaceuticals(Changzhou) Company Information
- 4.13.2 WATSON Pharmaceuticals(Changzhou) Business Overview
- 4.13.3 WATSON Pharmaceuticals(Changzhou) Olanzapine Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 WATSON Pharmaceuticals(Changzhou) Olanzapine Product Portfolio
- 4.13.5 WATSON Pharmaceuticals(Changzhou) Recent Developments
- 4.14 Zhejiang Langhua Pharmaceuticals
- 4.14.1 Zhejiang Langhua Pharmaceuticals Company Information
- 4.14.2 Zhejiang Langhua Pharmaceuticals Business Overview
- 4.14.3 Zhejiang Langhua Pharmaceuticals Olanzapine Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Zhejiang Langhua Pharmaceuticals Olanzapine Product Portfolio
- 4.14.5 Zhejiang Langhua Pharmaceuticals Recent Developments
5 Global Olanzapine Market Scenario by Region
- 5.1 Global Olanzapine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Olanzapine Sales by Region: 2021-2032
- 5.2.1 Global Olanzapine Sales by Region: 2021-2026
- 5.2.2 Global Olanzapine Sales by Region: 2027-2032
- 5.3 Global Olanzapine Revenue by Region: 2021-2032
- 5.3.1 Global Olanzapine Revenue by Region: 2021-2026
- 5.3.2 Global Olanzapine Revenue by Region: 2027-2032
- 5.4 North America Olanzapine Market Facts & Figures by Country
- 5.4.1 North America Olanzapine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Olanzapine Sales by Country (2021-2032)
- 5.4.3 North America Olanzapine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Olanzapine Market Facts & Figures by Country
- 5.5.1 Europe Olanzapine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Olanzapine Sales by Country (2021-2032)
- 5.5.3 Europe Olanzapine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Olanzapine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Olanzapine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Olanzapine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Olanzapine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Olanzapine Market Facts & Figures by Country
- 5.7.1 South America Olanzapine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Olanzapine Sales by Country (2021-2032)
- 5.7.3 South America Olanzapine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Olanzapine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Olanzapine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Olanzapine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Olanzapine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Olanzapine Sales by Type (2021-2032)
- 6.1.1 Global Olanzapine Sales by Type (2021-2032) & (Kg)
- 6.1.2 Global Olanzapine Sales Market Share by Type (2021-2032)
- 6.2 Global Olanzapine Revenue by Type (2021-2032)
- 6.2.1 Global Olanzapine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Olanzapine Revenue Market Share by Type (2021-2032)
- 6.3 Global Olanzapine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Olanzapine Sales by Application (2021-2032)
- 7.1.1 Global Olanzapine Sales by Application (2021-2032) & (Kg)
- 7.1.2 Global Olanzapine Sales Market Share by Application (2021-2032)
- 7.2 Global Olanzapine Revenue by Application (2021-2032)
- 7.2.1 Global Olanzapine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Olanzapine Revenue Market Share by Application (2021-2032)
- 7.3 Global Olanzapine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Olanzapine Value Chain Analysis
- 8.1.1 Olanzapine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Olanzapine Production Mode & Process
- 8.2 Olanzapine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Olanzapine Distributors
- 8.2.3 Olanzapine Customers
9 Global Olanzapine Analyzing Market Dynamics
- 9.1 Olanzapine Industry Trends
- 9.2 Olanzapine Industry Drivers
- 9.3 Olanzapine Industry Opportunities and Challenges
- 9.4 Olanzapine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst